In summary, induction therapy with low doses of ATG or anti-IL2 antagonists in cirrhotic patients with pretransplant renal dysfunction are good strategies for preserving posttransplant renal function, with the cost of ATG being much lower. The gene discussed is IL2; the disease is Abnormal renal physiology.